WARNINGS O
Clinical O
Worsening O
and O
Suicide O
Risk O
: O
Patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
, O
both O
adult O
and O
pediatric O
, O
may O
experience O
worsening O
of O
their O
depression B-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
and O
behavior O
( O
suicidality B-NonOSE_AE
) O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
whether O
or O
not O
they O
are O
taking O
antidepressant O
medications O
, O
and O
this O
risk O
may O
persist O
until O
significant O
remission O
occurs O
. O

Suicide B-NonOSE_AE
is O
a O
known O
risk O
of O
depression B-Not_AE_Candidate
and O
certain O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
and O
these O
disorders O
themselves O
are O
the O
strongest O
predictors O
of O
suicide B-NonOSE_AE
. O

There O
has O
been O
a O
long-standing O
concern O
, O
however O
, O
that O
antidepressants O
may O
have O
a O
role O
in O
inducing O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
and O
the O
emergence O
of O
suicidality B-OSE_Labeled_AE
in O
certain O
patients O
during O
the O
early O
phases O
of O
treatment O
. O

Pooled O
analyses O
of O
short-term O
placebo-controlled O
trials O
of O
antidepressant O
drugs O
( O
SSRIs O
and O
others O
) O
showed O
that O
these O
drugs O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
and O
behavior O
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
( O
ages O
18-24 O
) O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
MDD B-Not_AE_Candidate
, O
obsessive B-Not_AE_Candidate
compulsive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
OCD I-Not_AE_Candidate
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
24 O
short-term O
trials O
of O
9 O
antidepressant O
drugs O
in O
over O
4,400 O
patients O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
adults O
with O
MDD B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
295 O
short-term O
trials O
( O
median O
duration O
of O
2 O
months O
) O
of O
11 O
antidepressant O
drugs O
in O
over O
77,000 O
patients O
. O

There O
was O
considerable O
variation O
in O
risk O
of O
suicidality B-OSE_Labeled_AE
among O
drugs O
, O
but O
a O
tendency O
toward O
an O
increase O
in O
the O
younger O
patients O
for O
almost O
all O
drugs O
studied O
. O

There O
were O
differences O
in O
absolute O
risk O
of O
suicidality B-NonOSE_AE
across O
the O
different O
indications O
, O
with O
the O
highest O
incidence O
in O
MDD B-Not_AE_Candidate
. O

The O
risk O
differences O
( O
drug O
vs O
placebo O
) O
, O
however O
, O
were O
relatively O
stable O
within O
age O
strata O
and O
across O
indications O
. O

These O
risk O
differences O
( O
drug-placebo O
difference O
in O
the O
number O
of O
cases O
of O
suicidality B-NonOSE_AE
per O
1,000 O
patients O
treated O
) O
are O
provided O
in O
Table O
1 O
. O

Table O
1 O
Age O
Range O
Drug-Placebo O
Difference O
in O
Number O
of O
Cases O
of O
Suicidality B-OSE_Labeled_AE
per O
1,000 O
Patients O
Treated O
Increases O
Compared O
to O
Placebo O
< O
18 O
14 O
additional O
cases O
18-24 O
5 O
additional O
cases O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
case O
> O
=65 O
6 O
fewer O
cases O
No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
trials O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
trials O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

It O
is O
unknown O
whether O
the O
suicidality B-NonOSE_AE
risk O
extends O
to O
longer-term O
use O
, O
i.e. O
, O
beyond O
several O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
trials O
in O
adults O
with O
depression B-Not_AE_Candidate
that O
the O
use O
of O
antidepressants O
can O
delay O
the O
recurrence O
of O
depression B-NonOSE_AE
. O

All O
patients O
being O
treated O
with O
antidepressants O
for O
any O
indication O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
and O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
a O
course O
of O
drug O
therapy O
, O
or O
at O
times O
of O
dose O
changes O
, O
either O
increases O
or O
decreases O
. O

The O
following O
symptoms O
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
impulsivity B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
hypomania B-OSE_Labeled_AE
, O
and O
mania B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
adult O
and O
pediatric O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
as O
well O
as O
for O
other O
indications O
, O
both O
psychiatric O
and O
nonpsychiatric O
. O

Although O
a O
causal O
link O
between O
the O
emergence O
of O
such O
symptoms O
and O
either O
the O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
impulses I-NonOSE_AE
has O
not O
been O
established O
, O
there O
is O
concern O
that O
such O
symptoms O
may O
represent O
precursors O
to O
emerging O
suicidality B-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
the O
medication O
, O
in O
patients O
whose O
depression B-Not_AE_Candidate
is O
persistently O
worse O
, O
or O
who O
are O
experiencing O
emergent O
suicidality B-NonOSE_AE
or O
symptoms O
that O
might O
be O
precursors O
to O
worsening O
depression B-NonOSE_AE
or O
suicidality B-NonOSE_AE
, O
especially O
if O
these O
symptoms O
are O
severe O
, O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

If O
the O
decision O
has O
been O
made O
to O
discontinue O
treatment O
, O
medication O
should O
be O
tapered O
, O
as O
rapidly O
as O
is O
feasible O
, O
but O
with O
recognition O
that O
abrupt O
discontinuation O
can O
be O
associated O
with O
certain O
symptoms O
( O
see O
PRECAUTIONS O
and O
DOSAGE O
AND O
ADMINISTRATION O
: O
Discontinuation O
of O
Treatment O
With O
PAXIL O
, O
for O
a O
description O
of O
the O
risks O
of O
discontinuation O
of O
PAXIL O
) O
. O

Families O
and O
caregivers O
of O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
or O
other O
indications O
, O
both O
psychiatric O
and O
nonpsychiatric O
, O
should O
be O
alerted O
about O
the O
need O
to O
monitor O
patients O
for O
the O
emergence O
of O
agitation B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
the O
other O
symptoms O
described O
above O
, O
as O
well O
as O
the O
emergence O
of O
suicidality B-NonOSE_AE
, O
and O
to O
report O
such O
symptoms O
immediately O
to O
healthcare O
providers O
. O

Such O
monitoring O
should O
include O
daily O
observation O
by O
families O
and O
caregivers O
. O

Prescriptions O
for O
PAXIL O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
tablets O
consistent O
with O
good O
patient O
management O
, O
in O
order O
to O
reduce O
the O
risk O
of O
overdose B-NonOSE_AE
. O

Screening O
Patients O
for O
Bipolar O
Disorder O
: O
A O
major B-NonOSE_AE
depressive I-NonOSE_AE
episode I-NonOSE_AE
may O
be O
the O
initial O
presentation O
of O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

It O
is O
generally O
believed O
( O
though O
not O
established O
in O
controlled O
trials O
) O
that O
treating O
such O
an O
episode O
with O
an O
antidepressant O
alone O
may O
increase O
the O
likelihood O
of O
precipitation B-NonOSE_AE
of I-NonOSE_AE
a I-NonOSE_AE
mixed I-NonOSE_AE
/ I-NonOSE_AE
manic I-NonOSE_AE
episode I-NonOSE_AE
in O
patients O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Whether O
any O
of O
the O
symptoms O
described O
above O
represent O
such O
a O
conversion O
is O
unknown O
. O

However O
, O
prior O
to O
initiating O
treatment O
with O
an O
antidepressant O
, O
patients O
with O
depressive B-Not_AE_Candidate
symptoms I-Not_AE_Candidate
should O
be O
adequately O
screened O
to O
determine O
if O
they O
are O
at O
risk O
for O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
; O
such O
screening O
should O
include O
a O
detailed O
psychiatric B-Not_AE_Candidate
history O
, O
including O
a O
family B-Not_AE_Candidate
history I-Not_AE_Candidate
of I-Not_AE_Candidate
suicide I-Not_AE_Candidate
, O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
and O
depression B-Not_AE_Candidate
. O

It O
should O
be O
noted O
that O
PAXIL O
is O
not O
approved O
for O
use O
in O
treating O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
. O

Serotonin O
Syndrome O
: O
The O
development O
of O
a O
potentially O
life-threatening O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
has O
been O
reported O
with O
SNRIs O
and O
SSRIs O
, O
including O
PAXIL O
, O
alone O
but O
particularly O
with O
concomitant O
use O
of O
other O
serotonergic O
drugs O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
amphetamines O
, O
and O
St O
. O
John O
's O
Wort O
) O
and O
with O
drugs O
that O
impair O
metabolism O
of O
serotonin O
( O
in O
particular O
, O
MAOIs O
, O
both O
those O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
and O
also O
others O
, O
such O
as O
linezolid O
and O
intravenous O
methylene O
blue O
) O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
delirium B-NonOSE_AE
, O
and O
coma B-NonOSE_AE
) O
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
tremor B-NonOSE_AE
, O
rigidity B-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
, O
seizures B-NonOSE_AE
, O
and/or O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

Patients O
should O
be O
monitored O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

The O
concomitant O
use O
of O
PAXIL O
with O
MAOIs O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
is O
contraindicated O
. O

PAXIL O
should O
also O
not O
be O
started O
in O
a O
patient O
who O
is O
being O
treated O
with O
MAOIs O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
. O

All O
reports O
with O
methylene O
blue O
that O
provided O
information O
on O
the O
route O
of O
administration O
involved O
intravenous O
administration O
in O
the O
dose O
range O
of O
1 O
mg/kg O
to O
8 O
mg/kg O
. O

No O
reports O
involved O
the O
administration O
of O
methylene O
blue O
by O
other O
routes O
( O
such O
as O
oral O
tablets O
or O
local O
tissue O
injection O
) O
or O
at O
lower O
doses O
. O

There O
may O
be O
circumstances O
when O
it O
is O
necessary O
to O
initiate O
treatment O
with O
an O
MAOI O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
in O
a O
patient O
taking O
PAXIL O
. O

PAXIL O
should O
be O
discontinued O
before O
initiating O
treatment O
with O
the O
MAOI O
( O
see O
CONTRAINDICATIONS O
and O
DOSAGE O
AND O
ADMINISTRATION O
) O
. O

If O
concomitant O
use O
of O
PAXIL O
with O
certain O
other O
serotonergic O
drugs O
, O
i.e. O
, O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
buspirone O
, O
tryptophan O
, O
amphetamines O
, O
and O
St O
. O
John O
's O
Wort O
is O
clinically O
warranted O
, O
be O
aware O
of O
a O
potential O
increased O
risk O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
. O

Treatment O
with O
PAXIL O
and O
any O
concomitant O
serotonergic O
agents O
should O
be O
discontinued O
immediately O
if O
the O
above O
events O
occur O
and O
supportive O
symptomatic O
treatment O
should O
be O
initiated O
. O

Angle-Closure O
Glaucoma O
: O
The O
pupillary B-OSE_Labeled_AE
dilation I-OSE_Labeled_AE
that O
occurs O
following O
use O
of O
many O
antidepressant O
drugs O
including O
Paxil O
may O
trigger O
an O
angle B-OSE_Labeled_AE
closure I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
in O
a O
patient O
with O
anatomically B-Not_AE_Candidate
narrow I-Not_AE_Candidate
angles I-Not_AE_Candidate
who O
does O
not O
have O
a O
patent O
iridectomy O
. O

Potential O
Interaction O
With O
Thioridazine O
: O
Thioridazine O
administration O
alone O
produces O
prolongation B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
QTc I-NonOSE_AE
interval I-NonOSE_AE
, O
which O
is O
associated O
with O
serious O
ventricular B-NonOSE_AE
arrhythmias I-NonOSE_AE
, O
such O
as O
torsade B-NonOSE_AE
de I-NonOSE_AE
pointes I-NonOSE_AE
- O
type O
arrhythmias B-NonOSE_AE
, O
and O
sudden B-NonOSE_AE
death I-NonOSE_AE
. O

This O
effect O
appears O
to O
be O
dose O
related O
. O

An O
in O
vivo O
study O
suggests O
that O
drugs O
which O
inhibit O
CYP2D6 O
, O
such O
as O
paroxetine O
, O
will O
elevate O
plasma O
levels O
of O
thioridazine O
. O

Therefore O
, O
it O
is O
recommended O
that O
paroxetine O
not O
be O
used O
in O
combination O
with O
thioridazine O
( O
see O
CONTRAINDICATIONS O
and O
PRECAUTIONS O
) O
. O

Usage O
in O
Pregnancy O
: O
Teratogenic B-OSE_Labeled_AE
Effects I-OSE_Labeled_AE
: O
Epidemiological O
studies O
have O
shown O
that O
infants B-OSE_Labeled_AE
exposed I-OSE_Labeled_AE
to I-OSE_Labeled_AE
paroxetine I-OSE_Labeled_AE
in I-OSE_Labeled_AE
the I-OSE_Labeled_AE
first I-OSE_Labeled_AE
trimester I-OSE_Labeled_AE
of I-OSE_Labeled_AE
pregnancy I-OSE_Labeled_AE
have O
an O
increased O
risk O
of O
congenital B-OSE_Labeled_AE
malformations I-OSE_Labeled_AE
, O
particularly O
cardiovascular O
malformations O
. O

The O
findings O
from O
these O
studies O
are O
summarized O
below O
: O
* O
A O
study O
based O
on O
Swedish O
national O
registry O
data O
demonstrated O
that O
infants B-OSE_Labeled_AE
exposed I-OSE_Labeled_AE
to I-OSE_Labeled_AE
paroxetine I-OSE_Labeled_AE
during I-OSE_Labeled_AE
pregnancy I-OSE_Labeled_AE
( I-OSE_Labeled_AE
n I-OSE_Labeled_AE
= I-OSE_Labeled_AE
8 I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
) I-OSE_Labeled_AE
had I-OSE_Labeled_AE
an I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
risk I-OSE_Labeled_AE
of I-OSE_Labeled_AE
cardiovascular I-OSE_Labeled_AE
malformations I-OSE_Labeled_AE
( O
2 O
% O
risk O
in O
paroxetine-exposed O
infants O
) O
compared O
to O
the O
entire O
registry O
population O
( O
1 O
% O
risk O
) O
, O
for O
an O
odds O
ratio O
( O
OR O
) O
of O
1.8 O
( O
95 O
% O
confidence O
interval O
1.1 O
to O
2.8 O
) O
. O

No O
increase O
in O
the O
risk O
of O
overall B-NonOSE_AE
congenital I-NonOSE_AE
malformations I-NonOSE_AE
was O
seen O
in O
the O
paroxetine-exposed O
infants O
. O

The O
cardiac B-OSE_Labeled_AE
malformations I-OSE_Labeled_AE
in I-OSE_Labeled_AE
the I-OSE_Labeled_AE
paroxetine I-OSE_Labeled_AE
- I-OSE_Labeled_AE
exposed I-OSE_Labeled_AE
infants I-OSE_Labeled_AE
were O
primarily O
ventricular B-OSE_Labeled_AE
septal I-OSE_Labeled_AE
defects I-OSE_Labeled_AE
( I-OSE_Labeled_AE
VSDs I-OSE_Labeled_AE
) O
and O
atrial B-OSE_Labeled_AE
septal I-OSE_Labeled_AE
defects I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ASDs I-OSE_Labeled_AE
) O
. O

Septal B-NonOSE_AE
defects I-NonOSE_AE
range O
in O
severity O
from O
those O
that O
resolve O
spontaneously O
to O
those O
which O
require O
surgery O
. O

* O
A O
separate O
retrospective O
cohort O
study O
from O
the O
United O
States O
( O
United O
Healthcare O
data O
) O
evaluated O
5,956 O
infants O
of O
mothers O
dispensed O
antidepressants O
during O
the O
first O
trimester O
( O
n O
= O
815 O
for O
paroxetine O
) O
. O

This O
study O
showed O
a O
trend O
towards O
an O
increased O
risk O
for O
cardiovascular B-OSE_Labeled_AE
malformations I-OSE_Labeled_AE
for O
paroxetine O
( O
risk O
of O
1.5 O
% O
) O
compared O
to O
other O
antidepressants O
( O
risk O
of O
1 O
% O
) O
, O
for O
an O
OR O
of O
1.5 O
( O
95 O
% O
confidence O
interval O
0.8 O
to O
2.9 O
) O
. O

Of O
the O
12 O
paroxetine B-OSE_Labeled_AE
- I-OSE_Labeled_AE
exposed I-OSE_Labeled_AE
infants I-OSE_Labeled_AE
with I-OSE_Labeled_AE
cardiovascular I-OSE_Labeled_AE
malformations I-OSE_Labeled_AE
, O
9 O
had O
VSDs B-OSE_Labeled_AE
. O

This O
study O
also O
suggested O
an O
increased O
risk O
of O
overall O
major O
congenital B-OSE_Labeled_AE
malformations I-OSE_Labeled_AE
including O
cardiovascular O
defects O
for O
paroxetine O
( O
4 O
% O
risk O
) O
compared O
to O
other O
( O
2 O
% O
risk O
) O
antidepressants O
( O
OR O
1.8 O
; O
95 O
% O
confidence O
interval O
1.2 O
to O
2.8 O
) O
. O

* O
Two O
large O
case-control O
studies O
using O
separate O
databases O
, O
each O
with O
> O
9,000 O
birth B-NonOSE_AE
defect I-NonOSE_AE
cases O
and O
> O
4,000 O
controls O
, O
found O
that O
maternal O
use O
of O
paroxetine O
during O
the O
first O
trimester O
of O
pregnancy O
was O
associated O
with O
a O
2- O
to O
3-fold O
increased O
risk O
of O
right B-OSE_Labeled_AE
ventricular I-OSE_Labeled_AE
outflow I-OSE_Labeled_AE
tract I-OSE_Labeled_AE
obstructions I-OSE_Labeled_AE
. O

In O
one O
study O
the O
odds O
ratio O
was O
2.5 O
( O
95 O
% O
confidence O
interval O
, O
1.0 O
to O
6.0 O
, O
7 O
exposed O
infants O
) O
and O
in O
the O
other O
study O
the O
odds O
ratio O
was O
3.3 O
( O
95 O
% O
confidence O
interval O
, O
1.3 O
to O
8.8 O
, O
6 O
exposed O
infants O
) O
. O

Other O
studies O
have O
found O
varying O
results O
as O
to O
whether O
there O
was O
an O
increased O
risk O
of O
overall O
, O
cardiovascular B-NonOSE_AE
, O
or O
specific O
congenital I-NonOSE_AE
malformations I-NonOSE_AE
. O

A O
meta-analysis O
of O
epidemiological O
data O
over O
a O
16-year O
period O
( O
1992 O
to O
2008 O
) O
on O
first O
trimester O
paroxetine O
use O
in O
pregnancy B-Not_AE_Candidate
and O
congenital B-NonOSE_AE
malformations I-NonOSE_AE
included O
the O
above-noted O
studies O
in O
addition O
to O
others O
( O
n O
= O
17 O
studies O
that O
included O
overall O
malformations B-NonOSE_AE
and O
n O
= O
14 O
studies O
that O
included O
cardiovascular B-NonOSE_AE
malformations I-NonOSE_AE
; O
n O
= O
20 O
distinct O
studies O
) O
. O

While O
subject O
to O
limitations O
, O
this O
meta-analysis O
suggested O
an O
increased O
occurrence O
of O
cardiovascular B-OSE_Labeled_AE
malformations I-OSE_Labeled_AE
( O
prevalence O
odds O
ratio O
[ O
POR O
] O
1.5 O
; O
95 O
% O
confidence O
interval O
1.2 O
to O
1.9 O
) O
and O
overall O
malformations B-OSE_Labeled_AE
( O
POR O
1.2 O
; O
95 O
% O
confidence O
interval O
1.1 O
to O
1.4 O
) O
with O
paroxetine O
use O
during O
the O
first O
trimester O
. O

It O
was O
not O
possible O
in O
this O
meta-analysis O
to O
determine O
the O
extent O
to O
which O
the O
observed O
prevalence O
of O
cardiovascular B-NonOSE_AE
malformations I-NonOSE_AE
might O
have O
contributed O
to O
that O
of O
overall O
malformations B-NonOSE_AE
, O
nor O
was O
it O
possible O
to O
determine O
whether O
any O
specific O
types O
of O
cardiovascular B-NonOSE_AE
malformations I-NonOSE_AE
might O
have O
contributed O
to O
the O
observed O
prevalence O
of O
all O
cardiovascular B-NonOSE_AE
malformations I-NonOSE_AE
. O

If O
a O
patient O
becomes O
pregnant B-NonOSE_AE
while O
taking O
paroxetine O
, O
she O
should O
be O
advised O
of O
the O
potential O
harm B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Unless O
the O
benefits O
of O
paroxetine O
to O
the O
mother O
justify O
continuing O
treatment O
, O
consideration O
should O
be O
given O
to O
either O
discontinuing O
paroxetine O
therapy O
or O
switching O
to O
another O
antidepressant O
( O
see O
PRECAUTIONS O
: O
Discontinuation O
of O
Treatment O
With O
PAXIL O
) O
. O

For O
women O
who O
intend O
to O
become O
pregnant B-NonOSE_AE
or O
are O
in O
their O
first O
trimester O
of O
pregnancy B-Not_AE_Candidate
, O
paroxetine O
should O
only O
be O
initiated O
after O
consideration O
of O
the O
other O
available O
treatment O
options O
. O

Animal O
Findings O
: O
Reproduction O
studies O
were O
performed O
at O
doses O
up O
to O
50 O
mg/kg/day O
in O
rats O
and O
6 O
mg/kg/day O
in O
rabbits O
administered O
during O
organogenesis O
. O

These O
doses O
are O
approximately O
8 O
( O
rat O
) O
and O
2 O
( O
rabbit O
) O
times O
the O
maximum O
recommended O
human O
dose O
( O
MRHD O
) O
on O
an O
mg/m O
2 O
basis O
. O

These O
studies O
have O
revealed O
no O
evidence O
of O
teratogenic B-NonOSE_AE
effects I-NonOSE_AE
. O

However O
, O
in O
rats O
, O
there O
was O
an O
increase O
in O
pup O
deaths O
during O
the O
first O
4 O
days O
of O
lactation O
when O
dosing O
occurred O
during O
the O
last O
trimester O
of O
gestation O
and O
continued O
throughout O
lactation O
. O

This O
effect O
occurred O
at O
a O
dose O
of O
1 O
mg/kg/day O
or O
approximately O
one-sixth O
of O
the O
MRHD O
on O
an O
mg/m O
2 O
basis O
. O

The O
no-effect O
dose O
for O
rat O
pup O
mortality O
was O
not O
determined O
. O

The O
cause O
of O
these O
deaths B-NonOSE_AE
is O
not O
known O
. O

Nonteratogenic O
Effects O
: O
Neonates B-OSE_Labeled_AE
exposed O
to O
PAXIL O
and O
other O
SSRIs O
or O
serotonin O
and O
norepinephrine O
reuptake O
inhibitors O
( O
SNRIs O
) O
, O
late O
in O
the O
third O
trimester O
have O
developed O
complications O
requiring O
prolonged O
hospitalization O
, O
respiratory I-OSE_Labeled_AE
support O
, O
and O
tube O
feeding O
. O

Such O
complications O
can O
arise O
immediately O
upon O
delivery O
. O

Reported O
clinical O
findings O
have O
included O
respiratory O
distress I-OSE_Labeled_AE
, O
cyanosis O
, O
apnea O
, O
seizures O
, O
temperature O
instability O
, O
feeding O
difficulty O
, O
vomiting O
, O
hypoglycemia O
, O
hypotonia O
, O
hypertonia O
, O
hyperreflexia O
, O
tremor O
, O
jitteriness O
, O
irritability O
, O
and O
constant O
crying O
. O

These O
features O
are O
consistent O
with O
either O
a O
direct O
toxic O
effect O
of O
SSRIs O
and O
SNRIs O
or O
, O
possibly O
, O
a O
drug B-OSE_Labeled_AE
discontinuation I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

It O
should O
be O
noted O
that O
, O
in O
some O
cases O
, O
the O
clinical O
picture O
is O
consistent O
with O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
see O
WARNINGS O
: O
Serotonin B-NonOSE_AE
Syndrome I-NonOSE_AE
) O
. O

Infants O
exposed O
to O
SSRIs O
in O
pregnancy O
may O
have O
an O
increased O
risk O
for O
persistent O
pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
newborn I-OSE_Labeled_AE
( I-OSE_Labeled_AE
PPHN I-OSE_Labeled_AE
) O
. O

PPHN B-OSE_Labeled_AE
occurs O
in O
1 O
- O
2 O
per O
1,000 O
live O
births O
in O
the O
general O
population O
and O
is O
associated O
with O
substantial O
neonatal O
morbidity O
and O
mortality B-NonOSE_AE
. O

Several O
recent O
epidemiologic O
studies O
suggest O
a O
positive O
statistical O
association O
between O
SSRI O
use O
( O
including O
PAXIL O
) O
in O
pregnancy B-Not_AE_Candidate
and O
PPHN B-OSE_Labeled_AE
. O

Other O
studies O
do O
not O
show O
a O
significant O
statistical O
association O
. O

Physicians O
should O
also O
note O
the O
results O
of O
a O
prospective O
longitudinal O
study O
of O
201 O
pregnant B-Not_AE_Candidate
women O
with O
a O
history O
of O
major B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
who O
were O
either O
on O
antidepressants O
or O
had O
received O
antidepressants O
less O
than O
12 O
weeks O
prior O
to O
their O
last O
menstrual O
period O
, O
and O
were O
in O
remission O
. O

Women O
who O
discontinued O
antidepressant O
medication O
during O
pregnancy B-Not_AE_Candidate
showed O
a O
significant O
increase O
in O
relapse O
of O
their O
major O
depression B-Not_AE_Candidate
compared O
to O
those O
women O
who O
remained O
on O
antidepressant O
medication O
throughout O
pregnancy B-Not_AE_Candidate
. O

When O
treating O
a O
pregnant B-Not_AE_Candidate
woman O
with O
PAXIL O
, O
the O
physician O
should O
carefully O
consider O
both O
the O
potential O
risks O
of O
taking O
an O
SSRI O
, O
along O
with O
the O
established O
benefits O
of O
treating O
depression B-Not_AE_Candidate
with O
an O
antidepressant O
. O

This O
decision O
can O
only O
be O
made O
on O
a O
case O
by O
case O
basis O
( O
see O
DOSAGE O
AND O
ADMINISTRATION O
and O
ADVERSE O
REACTIONS O
: O
Postmarketing O
Reports O
) O
. O

